High-intensity care for GDMT titration
J Biegus, M Pagnesi, B Davison, P Ponikowski… - Heart Failure …, 2024 - Springer
Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality,
increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic …
increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic …
[HTML][HTML] Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure
R Sato, MJ Koziolek, S von Haehling - European Journal of Internal …, 2024 - Elsevier
Mineral abnormalities are a common complication of heart failure (HF). In particular,
dyskalaemia, hyponatraemia, and hypomagnesaemia are prevalent, with hypo-and …
dyskalaemia, hyponatraemia, and hypomagnesaemia are prevalent, with hypo-and …
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a network meta-analysis of 32 randomized trials
K Pamporis, P Karakasis, M Sagris, I Zarifis… - Current Problems in …, 2024 - Elsevier
Introduction Several randomized controlled trials (RCTs) have examined mineralocorticoid
receptor antagonists (MRAs) in heart failure (HF) with reduced ejection fraction (HFrEF). This …
receptor antagonists (MRAs) in heart failure (HF) with reduced ejection fraction (HFrEF). This …
Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction
Background Soluble guanylate cyclase (sGC) stimulators have been investigated for heart
failure (HF) in several randomized controlled trials (RCTs). However, its place in the …
failure (HF) in several randomized controlled trials (RCTs). However, its place in the …
Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders
C Fonseca, C Garagarza, G Silva, G Caires… - Heart Failure …, 2024 - Springer
Hyperkalemia is a potentially life-threatening condition frequently encountered in clinical
practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and …
practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and …
Angiotensin‐converting enzyme inhibitors attenuate circulating CAF22 and physical decline in congestive heart failure: Diagnostic implications of CAF22
Aims Age‐associated muscle loss, termed sarcopenia is the major cause of physical
disability in patients with congestive heart failure (CHF). Angiotensin‐converting enzyme …
disability in patients with congestive heart failure (CHF). Angiotensin‐converting enzyme …